Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Alto Neuroscience, Inc. (ANRO)
NYSE:ANRO
RESEARCH TOOLSreports
Holding ANRO?
Track your performance easily
ANRO Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.61 - $24.00
Previous Close$4.27
Volume779.05K
Average Volume (3M)766.03K
Market Cap
$120.83M
Enterprise Value-$44.80M
Total Cash (Recent Filing)$181.70M
Total Debt (Recent Filing)$16.07M
Price to Earnings (P/E)―
Beta2.62
Next Earnings
Mar 20, 2025EPS Estimate
-$0.64Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.13
Shares Outstanding26,970,168
10 Day Avg. Volume532,303
30 Day Avg. Volume766,032
Standard Deviation0.25
R-Squared0.02
Alpha-0.13
Financial Highlights & Ratios
Price to Book (P/B)0.70
Price to Sales (P/S)15.30
Price to Cash Flow (P/CF)-2.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda1.38
Forecast
1Y Price Target
$12.50Price Target Upside205.62% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
Alto Neuroscience, Inc. News
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressThe ALTO-300 readout is seen as a somewhat more derisked program given that it is an approved therapy in Europe.
Financial StabilityThe company has a cash runway into 2027, providing financial stability for ongoing and future trials.
Regulatory EngagementANRO had a constructive Type C meeting with the FDA about ALTO-100's registrational pathway, indicating positive regulatory engagement.
Bears Say
Clinical Trial ResultsALTO-100 was discontinued in MDD with poor cognition after failing to meet the primary endpoint in the Ph2b study.
Research And DevelopmentAlto's first shot at its precision psychiatry approach failed to materialize in a successful study.
Study Non-complianceHigher-than-anticipated non-compliance was observed in the monotherapy group of the Ph2b study.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
ANRO FAQ
What was Alto Neuroscience, Inc.’s price range in the past 12 months?
Alto Neuroscience, Inc. lowest stock price was $3.61 and its highest was $24.00 in the past 12 months.
What is Alto Neuroscience, Inc.’s market cap?
Currently, no data Available
When is Alto Neuroscience, Inc.’s upcoming earnings report date?
Alto Neuroscience, Inc.’s upcoming earnings report date is Mar 20, 2025 which is in 118 days.
How were Alto Neuroscience, Inc.’s earnings last quarter?
Alto Neuroscience, Inc. released its earnings results on Nov 12, 2024. The company reported -$0.62 earnings per share for the quarter, beating the consensus estimate of -$0.65 by $0.03.
Is Alto Neuroscience, Inc. overvalued?
According to Wall Street analysts Alto Neuroscience, Inc.’s price is currently Undervalued.
Does Alto Neuroscience, Inc. pay dividends?
Alto Neuroscience, Inc. does not currently pay dividends.
What is Alto Neuroscience, Inc.’s EPS estimate?
Alto Neuroscience, Inc.’s EPS estimate is -$0.64.
How many shares outstanding does Alto Neuroscience, Inc. have?
Alto Neuroscience, Inc. has 26,970,167 shares outstanding.
What happened to Alto Neuroscience, Inc.’s price movement after its last earnings report?
Alto Neuroscience, Inc. reported an EPS of -$0.62 in its last earnings report, beating expectations of -$0.65. Following the earnings report the stock price went up 0.667%.
Which hedge fund is a major shareholder of Alto Neuroscience, Inc.?
Among the largest hedge funds holding Alto Neuroscience, Inc.’s share is Falcon Edge Capital, LP. It holds Alto Neuroscience, Inc.’s shares valued at 42M.
---
Alto Neuroscience, Inc. Stock Smart Score
Company Description
Alto Neuroscience, Inc.
Alto Neuroscience is a clinical-stage biopharmaceutical company with a mission to redefine neuropsychiatric care by leveraging neurobiology to develop personalized and highly effective treatment options. Through our AI-enabled biomarker platform, we combine rich sources of information on patients¿ brain activity and behavior to better identify which patients are more likely to respond to our novel product candidates.
---
ANRO Stock 12 Month Forecast
Average Price Target
$12.50
▲(205.62% Upside)
Technical Analysis
Best Analysts Covering ANRO
1 Year
1 Year Success Rate
0/7 ratings generated profit
1 Year Average Return
-58.61%
assigned a buy rating 9 days ago
Copying Ritu Baral's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -58.61% per trade.
---